Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this


Our History

Pioneers in pain research

We have invested heavily in R&D to produce an extensive portfolio of pain treatments. We are proud of our past achievements, each one helping us get closer to a world without pain. We launched opioid pain medication, Tramal®, in the seventies as a fast-acting solution for patients in severe pain, and it remains a first-choice for pain relief around the world today. We are continuing to invest in disease understanding, research and development, and hope to further improve patient outcomes, with several innovative and exciting products currently under development.

A timeline of our major achievements in pain research

Tramal® launched – worldwide partnering
Global launches (Zaldiar®, Transtec®)
since 2000
Versatis® obtains approval in EU (UK), followed by first European launch in the UK.
Approval of Tapentadol in the US
EU submission of Tapentadol for acute and chronic pain, launch of Nucynta® in the US by Johnson & Johnson
Marketing authorisation of Tapentadol IR and PR in 26 EU countries
Market introduction in the United States of INTAC®, an innovative formulation technology for the protection of intended drug action.
FDA approval and launch of Tapentadol ER for chronic pain.
Palexia® is available in UK, Spain, Italy, Denmark, Sweden, Ireland, Portugal, Norway, Belgium and Switzerland.
Grünenthal and AcelRx enter into partnership for EU commercialisation of ZALVISO®.
Versatis® is registered in 28 countries in the EU and worldwide in 48 countries.
Launch of Recivit® in the Netherlands, Denmark, UK and France.
Distribution of Arcoxia® in several European countries.
Launch of ZALVISO®.
US-based Thar Pharmaceuticals Inc. acquired.
Licensing agreement entered into with AstraZeneca for the exclusive rights to Zurampic™ in Europe and Latin America.
Agreement entered into with AstraZeneca for the global rights to Zomig®, excluding Japan.

Leaders in Pain Research

We want to re-define the field of pain, creating specialised treatments through patient-inspired R&D.

Our Approach

We understand pain is not just a symptom but also an entire condition in itself that requires specialised treatment.

Share this with:

These are external links and will open in a new window